IDEAYA Biosciences (IDYA) Q3 2026 earnings summary

Executive summary

• Q3 collaboration revenue was $10.242M; net loss was $125.749M, versus $119.2M net income in Q3 2025, as operating expenses increased.

• Darovasertib plus crizotinib mUM NDA was submitted under FDA’s RTOR program; quarter-end cash, cash equivalents and marketable securities totaled $1.15B.

Financial highlights

• Q3 collaboration revenue was $10.242M vs. $8.9M in Q2; R&D expense was $121.6M vs. $108.7M and G&A was $26.3M vs. $22.5M.

• Nine-month collaboration revenue was $25.7M vs. $207.8M in 2025, reflecting prior-year Servier upfront license revenue; R&D was $326.0M and G&A was $68.1M.

• Q3 operating loss was $137.632M and net loss $125.749M, vs. $122.3M and $112.5M in Q2; nine-month net loss was $336.7M vs. $30.4M in 2025.

• Nine-month operating loss was $368.5M vs. $64.7M in 2025; R&D and G&A expenses rose 43% and 53% year over year, respectively.

Outlook and guidance

• Cash runway guidance into 2030 remains unchanged under the current operating plan; financial statements also state available liquidity is expected to fund planned operations for at least 12 months from report issuance.

• Initial global IDE849 Phase 1/2 data are targeted by year-end 2026 or early 2027; two Phase 3 trials in ES-SCLC and NEC are planned to start by year-end 2026, subject to development progress.

• IDE397 expansion is planned for H1 2027, initially focused on MTAP-deleted NSCLC; IDE034 initial Phase 1 data are targeted for 2027.

• IDE892 plus RG6505 trial initiation in MTAP-deleted, RAS-mutant PDAC is targeted by year-end 2026.